These 4 Measures Indicate That Andersons (NASDAQ:ANDE) Is Using Debt Extensively

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know worries about. It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when a business collapses. We can see that The Andersons, Inc. (NASDAQ:ANDE) does use debt in its business. But the real question is whether this debt is making the company risky.

Advertisement

When Is Debt A Problem?

Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. Part and parcel of capitalism is the process of 'creative destruction' where failed businesses are mercilessly liquidated by their bankers. While that is not too common, we often do see indebted companies permanently diluting shareholders because lenders force them to raise capital at a distressed price. By replacing dilution, though, debt can be an extremely good tool for businesses that need capital to invest in growth at high rates of return. When we examine debt levels, we first consider both cash and debt levels, together.

View our latest analysis for Andersons

How Much Debt Does Andersons Carry?

You can click the graphic below for the historical numbers, but it shows that as of December 2019 Andersons had US$1.20b of debt, an increase on US$723.3m, over one year. However, because it has a cash reserve of US$54.9m, its net debt is less, at about US$1.15b.

NasdaqGS:ANDE Historical Debt, March 11th 2020
NasdaqGS:ANDE Historical Debt, March 11th 2020

How Strong Is Andersons's Balance Sheet?

The latest balance sheet data shows that Andersons had liabilities of US$1.44b due within a year, and liabilities of US$1.27b falling due after that. Offsetting this, it had US$54.9m in cash and US$536.4m in receivables that were due within 12 months. So its liabilities total US$2.11b more than the combination of its cash and short-term receivables.

This deficit casts a shadow over the US$539.2m company, like a colossus towering over mere mortals. So we definitely think shareholders need to watch this one closely. After all, Andersons would likely require a major re-capitalisation if it had to pay its creditors today.

We measure a company's debt load relative to its earnings power by looking at its net debt divided by its earnings before interest, tax, depreciation, and amortization (EBITDA) and by calculating how easily its earnings before interest and tax (EBIT) cover its interest expense (interest cover). The advantage of this approach is that we take into account both the absolute quantum of debt (with net debt to EBITDA) and the actual interest expenses associated with that debt (with its interest cover ratio).

While we wouldn't worry about Andersons's net debt to EBITDA ratio of 4.9, we think its super-low interest cover of 1.5 times is a sign of high leverage. In large part that's due to the company's significant depreciation and amortisation charges, which arguably mean its EBITDA is a very generous measure of earnings, and its debt may be more of a burden than it first appears. It seems clear that the cost of borrowing money is negatively impacting returns for shareholders, of late. Looking on the bright side, Andersons boosted its EBIT by a silky 75% in the last year. Like the milk of human kindness that sort of growth increases resilience, making the company more capable of managing debt. The balance sheet is clearly the area to focus on when you are analysing debt. But it is future earnings, more than anything, that will determine Andersons's ability to maintain a healthy balance sheet going forward. So if you want to see what the professionals think, you might find this free report on analyst profit forecasts to be interesting.

But our final consideration is also important, because a company cannot pay debt with paper profits; it needs cold hard cash. So it's worth checking how much of that EBIT is backed by free cash flow. During the last three years, Andersons burned a lot of cash. While that may be a result of expenditure for growth, it does make the debt far more risky.

Our View

To be frank both Andersons's conversion of EBIT to free cash flow and its track record of staying on top of its total liabilities make us rather uncomfortable with its debt levels. But at least it's pretty decent at growing its EBIT; that's encouraging. Overall, it seems to us that Andersons's balance sheet is really quite a risk to the business. For this reason we're pretty cautious about the stock, and we think shareholders should keep a close eye on its liquidity. The balance sheet is clearly the area to focus on when you are analysing debt. However, not all investment risk resides within the balance sheet - far from it. For instance, we've identified 5 warning signs for Andersons (1 is a bit unpleasant) you should be aware of.

When all is said and done, sometimes its easier to focus on companies that don't even need debt. Readers can access a list of growth stocks with zero net debt 100% free, right now.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

About NasdaqGS:ANDE

Andersons

Operates as an agriculture and renewable fuels company in the United States, Canada, Mexico, and internationally.

Undervalued with solid track record.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1155.3% undervalued
51 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative
BL
BlackGoat
IREN logo
BlackGoat on IREN ·

IREN's Bold Moves in Sustainable Bitcoin Mining & AI Data Centers

Fair Value:US$71.4849.2% undervalued
205 users have followed this narrative
6 users have commented on this narrative
32 users have liked this narrative
HE
HedgeY
ARM logo
HedgeY on Arm Holdings ·

The Architecture Layer of AI Computing - But Priced Like the Future Already Arrived?

Fair Value:US$43038.1% undervalued
9 users have followed this narrative
1 users have commented on this narrative
3 users have liked this narrative
HI
Hidden_Rock_Capital
FISV logo
Hidden_Rock_Capital on Fiserv ·

Temporary "perfect storm" leads to opportunity to buy financial services leader for less than 5x long-term earnings

Fair Value:US$119.9956.4% undervalued
13 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative

Updated Narratives

ON
LOT logo
Ontological on Lotus Technology ·

Lotus Tech, Finloop and FOMO Pay Collaborate to Explore Vehicle Tokenization

Fair Value:US$2.463.9% undervalued
1 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative
NE
AIIO logo
newsfinder11221 on Robo.ai ·

Robo.ai (NASDAQ: AIIO): Building the Infrastructure Behind the AI Revolution

Fair Value:US$540.4% undervalued
1 users have followed this narrative
3 users have commented on this narrative
0 users have liked this narrative
EU
European_Hidden_Gem_Stocks
ALMIN logo
European_Hidden_Gem_Stocks on MINT Société anonyme ·

Mint SA: A French Micro-Cap Energy Retailer Worth Watching

Fair Value:€1153.1% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.917.3% undervalued
88 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28029.8% undervalued
199 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.7% undervalued
73 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0